Reviva Total Operating Expenses vs Income Before Tax Analysis
| RVPH Stock | USD 1.14 0.02 1.79% |
Reviva Pharmaceuticals financial indicator trend analysis is much more than just breaking down Reviva Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Reviva Pharmaceuticals is a good investment. Please check the relationship between Reviva Pharmaceuticals Total Operating Expenses and its Income Before Tax accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Total Operating Expenses vs Income Before Tax
Total Operating Expenses vs Income Before Tax Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Reviva Pharmaceuticals Total Operating Expenses account and Income Before Tax. At this time, the significance of the direction appears to have pay attention.
The correlation between Reviva Pharmaceuticals' Total Operating Expenses and Income Before Tax is -1.0. Overlapping area represents the amount of variation of Total Operating Expenses that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Reviva Pharmaceuticals Holdings, assuming nothing else is changed. The correlation between historical values of Reviva Pharmaceuticals' Total Operating Expenses and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Operating Expenses of Reviva Pharmaceuticals Holdings are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Total Operating Expenses i.e., Reviva Pharmaceuticals' Total Operating Expenses and Income Before Tax go up and down completely randomly.
Correlation Coefficient | -1.0 |
| Relationship Direction | Negative |
| Relationship Strength | Strong |
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Reviva Pharmaceuticals income statement and is an important metric when analyzing Reviva Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most indicators from Reviva Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Reviva Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. The Reviva Pharmaceuticals' current Enterprise Value is estimated to increase to about 104.2 M, while Tax Provision is projected to decrease to 9,973.
| 2021 | 2022 | 2023 | 2024 (projected) | Tax Provision | 6.0K | 20.8K | 16.9K | 10.0K | Income Tax Expense | 6.0K | 20.8K | 23.9K | 25.1K |
Reviva Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Reviva Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Reviva Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | (123.0K) | (683.3K) | 1.3M | (1.0M) | (900.6K) | (855.6K) | |
| Total Current Liabilities | 6.8M | 1.3M | 2.3M | 6.0M | 17.2M | 18.0M | |
| Net Tangible Assets | (35.9M) | 7.4M | 28.7M | 12.3M | 14.2M | 14.9M | |
| Retained Earnings | (54.5M) | (58.3M) | (66.8M) | (91.2M) | (134.4M) | (127.6M) | |
| Accounts Payable | 224.5K | 1.0M | 509.6K | 3.5M | 3.8M | 4.0M | |
| Total Current Assets | 193.0 | 8.8M | 31.4M | 18.9M | 23.7M | 15.2M |
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (2.34) | Return On Equity (17.95) |
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.